Status:

TERMINATED

Connected Catheter - Safety and Effectiveness Study

Lead Sponsor:

Spinal Singularity

Collaborating Sponsors:

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Conditions:

Neurogenic Bladder

Urinary Retention

Eligibility:

MALE

18+ years

Phase:

NA

Brief Summary

The Connected Catheter is a fully internal, urethral indwelling urinary prosthesis designed for improved bladder management in males with urinary retention disorders requiring catheterization. It is a...

Detailed Description

Spinal Singularity has developed the Connected Catheter System to address several drawbacks of urinary catheters. The Connected Catheter is fully internal, indwelling urinary prosthesis designed for i...

Eligibility Criteria

Inclusion

  • Males age ≥ 18 with clinical diagnosis of significant urinary retention
  • Must be clinically suitable and capable of safely managing bladder using an intermittent voiding or indwelling strategy
  • Must have stable urinary management history as determined by the investigator OR:
  • Must have urodynamic profile suitable for Gen 2 Connected Catheter (including bladder capacity \> 200mL without uninhibited bladder contractions)
  • Subject's lower urinary tract anatomy must fall within the ranges serviceable by the Gen 2 Connected Catheter device, as specified in the Investigational Device Instructions for Use (IFU).

Exclusion

  • Active symptomatic urinary tract infection, as defined in this clinical investigation protocol (subjects may receive the device after UTI has been treated)
  • Significant risk profile or recent history of urethral stricture (e.g. stricture within past 90 days)
  • Significant risk profile or recent history of clinically significant (uncontrolled) autonomic dysreflexia
  • Significant intermittent urinary incontinence (between catheterizations)
  • Uninhibited bladder contractions and/or Vesicoureteral reflux that is not reliably controlled with medication or alternate therapy (e.g. Botox injection)
  • Pre-existing urinary pathologies and/or morphological abnormalities of the lower urinary tract or bladder (assessed during in-depth medical screening, including cystoscopy and urine analysis)
  • Urinary tract inflammation or neoplasm
  • Urinary fistula
  • Bladder diverticulum (outpouching) \> 5cm in size
  • Chronic pyelonephritis (secondary to upper urinary tract infection(s) within past 6 months)
  • Impaired kidney function or renal failure
  • Active gross hematuria
  • Active urethritis
  • Dependence on an electro-magnetic medical implant (e.g. cardiac pacemaker or implanted drug pump) or external device
  • Any unsuitable comorbidities as determined by the Investigator or complications related to use of certain medications
  • Any physical or cognitive impairments that diminish the subject's ability to follow directions or otherwise safely use the Gen 2 Connected Catheter System
  • Catheter Assessment Tool screening yields unacceptable results

Key Trial Info

Start Date :

October 1 2020

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 7 2021

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT04059159

Start Date

October 1 2020

End Date

April 7 2021

Last Update

January 20 2023

Active Locations (3)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (3 locations)

1

Rancho Los Amigos Rehabiliation Hospital

Downey, California, United States, 90242

2

UC San Diego

San Diego, California, United States, 92093

3

MedStar National Rehabilitation Hospital

Washington D.C., District of Columbia, United States, 20010